- Home
- SKBL vs MREO Comparison
SKBL vs MREO Comparison
Compare SKBL & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKBL
- MREO
- Stock Information
- Founded
- SKBL 2012
- MREO 2015
- Country
- SKBL Hong Kong
- MREO United Kingdom
- Employees
- SKBL N/A
- MREO N/A
- Industry
- SKBL
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- SKBL
- MREO Health Care
- Exchange
- SKBL NYSE
- MREO Nasdaq
- Market Cap
- SKBL 302.6M
- MREO 424.5M
- IPO Year
- SKBL 2025
- MREO N/A
- Fundamental
- Price
- SKBL $10.14
- MREO $2.19
- Analyst Decision
- SKBL
- MREO Strong Buy
- Analyst Count
- SKBL 0
- MREO 7
- Target Price
- SKBL N/A
- MREO $7.71
- AVG Volume (30 Days)
- SKBL 756.1K
- MREO 943.2K
- Earning Date
- SKBL 01-01-0001
- MREO 05-13-2025
- Dividend Yield
- SKBL N/A
- MREO N/A
- EPS Growth
- SKBL N/A
- MREO N/A
- EPS
- SKBL 0.03
- MREO N/A
- Revenue
- SKBL $49,638,709.00
- MREO N/A
- Revenue This Year
- SKBL N/A
- MREO N/A
- Revenue Next Year
- SKBL N/A
- MREO $54.91
- P/E Ratio
- SKBL $321.58
- MREO N/A
- Revenue Growth
- SKBL 9.58
- MREO N/A
- 52 Week Low
- SKBL $3.68
- MREO $1.58
- 52 Week High
- SKBL $14.25
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- SKBL N/A
- MREO 43.17
- Support Level
- SKBL N/A
- MREO $2.11
- Resistance Level
- SKBL N/A
- MREO $2.27
- Average True Range (ATR)
- SKBL 0.00
- MREO 0.13
- MACD
- SKBL 0.00
- MREO -0.02
- Stochastic Oscillator
- SKBL 0.00
- MREO 16.41
About SKBL SKYLINE BUILDERS GROUP HOLDING LIMI
Skyline Builders Group Holding Ltd is an holding company operates through its subsidiary. It is a Public Works Contractor company undertaking roads and drainage in Hong Kong. Its construction activities mainly include public civil engineering works, such as road and drainage works, in Hong Kong.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).